ArticleScientific reports2025
Prognostic value of the Braden scale for short-term mortality in critically ill patients with traumatic brain injury.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Admission Braden Scale Score Is Associated with In-Hospital Mortality in ICU Patients Admitted After a Same-Level Fall: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Traumatic brain injury (TBI) is a leading cause of global mortality and disability. Early identification of mortality risk factors is crucial for improving outcomes. The Braden Scale score, a routinely collected nursing assessment tool originally designed for pressure injury risk assessment, has been underexplored for mortality prediction in TBI patients. This study aimed to evaluate the association between Braden Scale scores at ICU admission and short-term all-cause mortality in TBI patients. This retrospective cohort study utilized the MIMIC-IV database as the derivation cohort and the eICU-CRD database for external validation. Adult TBI patients with complete Braden Scale assessments and outcome data were included. The primary exposure was the initial Braden Scale score, categorized into low and high groups based on the median value. Outcomes included 28 days and 60 days all-cause mortality in both hospital and ICU settings. We also evaluate the components of braden scores by cox regression for outcoms. Statistical analyses included multivariable Cox regression, restricted cubic splines, subgroup analyses, and assessments of predictive performance using IDI, NRI, ROC curves, and decision curve analysis. A total of 2355 patients were analyzed. The low Braden score group showed significantly higher mortality across all endpoints: hospital 28 days (48.1% vs. 19.7%), hospital 60 days (49.4% vs. 20.7%), ICU 28 days (46.2% vs. 18.9%), and ICU 60 days (47.6% vs. 19.8%) (all p < 0.001). After multivariable adjustment, low Braden scores remained independently associated with mortality, with adjusted hazard ratios ranging from 1.78 to 1.84. In a cox regression analysis for the components of Braden Scale, we identified significant inverse associations of sensory perception, activity, nutrition, and friction/shear with multiple mortality outcomes. A nonlinear dose-response relationship was observed, with mortality risk increasing sharply at scores below 12-15. Subgroup analyses indicated a more pronounced association in patients aged ≤ 65 years, while the association was attenuated in those with renal disease. The Braden score demonstrated robust discriminative ability (AUCs: 0.77-0.82) and clinical utility in decision curve analysis. The Braden Scale score is a strong, independent, and readily available predictor and risk factor of short-term mortality in TBI patients, demonstrating a nonlinear inverse relationship with death risk. Subitem analysis further identified sensory perception, activity, nutrition, and friction/shear as key components significantly associated with reduced mortality. These properties support its practical utility for risk stratification at the bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.